

K092691

## 510(K) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92(c).

The assigned 510(k) number is: \_\_\_\_\_.

OCT 1 5 2009

### 1. Submitter:

Shenzhen Mindray Bio-medical Electronics Co., LTD  
Mindray Building, Keji 12th Road South, Hi-tech Industrial Park, Nanshan, Shenzhen,  
518057, P. R. China

Tel: +86 755 8611 9549

Fax: +86 755 2658 2680

### Contact Person:

Sheng Haobin

Shenzhen Mindray Bio-medical Electronics Co., LTD  
Mindray Building, Keji 12th Road South, Hi-tech Industrial Park,  
Nanshan, Shenzhen, 518057, P. R. China

Date Prepared: July 31, 2009

### 2. Device Name: DC-7 Diagnostic Ultrasound System

#### Classification

Regulatory Class: II

Review Category: Tier II

21 CFR 892.1550 Ultrasonic Pulsed Doppler Imaging System (90-IYN)

21 CFR 892.1560 Ultrasonic Pulsed Echo Imaging System (90-IYO)

21 CFR 892.1570 Diagnostic Ultrasound Transducer (90-ITX)

### 3. Marketed Device:

DC-7 Diagnostic Ultrasound System is substantially equivalent to the following devices:  
Mindray DC-3 (K#091491), Mindray DC-6 (K#072164), GE Vivid S6 (K#071985),  
Siemens X300 (K#090276), GE Logiq P5 (K#060993), GE Vivid 7 (K#060542).

#### **4. Device Description:**

The DC-7 Diagnostic Ultrasound System is a general purpose, portable, software controlled, ultrasound diagnostic system. This system is a Track 3 device that employs an array of probes that include linear array probe, convex array probe, phased array probe and volume probe with a frequency range of approximately 2.0 MHz to 12.0 MHz.

#### **5. Intended Use:**

The DC-7 diagnostic ultrasound system is designed for M, B, pulsed doppler, continuous Doppler, color Doppler, power Doppler modes, and combined modes (i.e. B/M Mode). The system is indicated for fetal, abdominal, pediatric, small organ (breast, thyroid, and testes), cephalic (neonatal and adult), transrectal, transvaginal, peripheral vascular, musculo-skeletal (conventional and superficial), and cardiac (neonatal and adult). The system includes optional biopsy needle guides that attach to the transducers.

#### **6. Safety Considerations:**

The DC-7 Diagnostic Ultrasound System had been tested as Track 3 Device per the FDA Guidance document "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers" issued in September 2008. The acoustic output is measured and calculated per NEMA UD 2: 2004 Acoustic Output Measurement Standard for Diagnostic Ultrasound Equipment and NEMA UD 3: 2004 Standards for Real-Time Display of Thermal and Mechanical Acoustic Output Indices on Diagnostic Ultrasound Equipment. The device conforms to applicable medical device safety standards, such as IEC 60601-1, IEC 60601-1-1, IEC 60601-1-2, IEC 60601-2-37, IEC 60601-1-4 and ISO 10993-1.

#### **Conclusion:**

The conclusions drawn from testing of the DC-7 Diagnostic Ultrasound System demonstrate that the device is as safe and effective as the legally marketed predicate devices.



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room W-O66-0609  
Silver Spring, MD 20993-0002

JAN - 4 2010

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.  
% Mr. Robert Mosenkis  
President  
CITECH  
5200 Butler Pike  
PLYMOUTH MEETING PA 19462-1298

Re: K092691

Trade/Device Name: DC-7 Diagnostic Ultrasound System  
Regulation Number: 21 CFR 892.1550  
Regulation Name: Ultrasonic pulsed Doppler imaging system  
Regulatory Class: II  
Product Code: IYN, IYO, and ITX  
Dated: September 29, 2009  
Received: September 30, 2009

Dear Mr. Mosenkis:

This letter corrects our substantially equivalent letter of October 15, 2009.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

This determination of substantial equivalence applies to the following transducers intended for use with the DC-7 Diagnostic Ultrasound System, as described in your premarket notification:

Transducer Model Number

3C5A, C5-2  
V10-4, V10-4B  
6C2  
7L4A, 7L5, L12-4, L7-3, L11-4

L14-6  
2P2  
4CD4

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

If you have any questions regarding the content of this letter, please contact Mr. Paul Hardy at (301) 796-6542.

Sincerely yours,

  
for Janine M. Morris  
Acting Director, Division of Reproductive,  
Abdominal, and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure(s)

## Diagnostic Ultrasound Indications for Use Form

System X Transducer \_\_\_\_\_  
 Model: DC-7  
 510(k) Number(s) \_\_\_\_\_

Clinical Application	Mode of Operation							
	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Combined (specify)	Other (specify)
Ophthalmic								
Fetal	N	N	N		N	N	N	Note 1, 2, 3, 4, 7, 8
Abdominal	N	N	N	N	N	N	N	Note 1, 2, 3, 4, 5, 7, 8
Intraoperative (specify)*								
Intraoperative (Neuro)								
Laparoscopic								
Pediatric	N	N	N	N	N	N	N	Note 1, 2, 4, 5, 7, 8
Small organ(specify)**	N	N	N		N	N	N	Note 1, 2, 4, 7, 8
Neonatal Cephalic	N	N	N	N	N	N	N	Note 1, 2, 4, 5, 7, 8
Adult Cephalic	N	N	N	N	N	N	N	Note 1, 2, 4, 5, 7, 8
Trans-rectal	N	N	N		N	N	N	Note 1, 2, 4, 7, 8
Trans-vaginal	N	N	N		N	N	N	Note 1, 2, 4, 7, 8
Trans-urethral								
Trans-esoph.(non-Card.)								
Musculo-skeletal Conventional	N	N	N		N	N	N	Note 1, 2, 4, 7, 8
Musculo-skeletal Superficial	N	N	N		N	N	N	Note 1, 2, 4, 7, 8
Intravascular								
Cardiac Adult	N	N	N	N	N	N	N	Note 1, 2, 5, 7, 8
Cardiac Pediatric	N	N	N	N	N	N	N	Note 1, 2, 5, 7, 8
Intravascular (Cardiac)								
Trans-esoph.(Cardiac)								
Intra-Cardiac								
Peripheral Vascular	N	N	N		N	N	N	Note 1, 2, 4, 7, 8
Other (specify)***								

N=new indication; P=previously cleared by FDA; E=added under Appendix E

Additional comments: Combined modes: B+M, PW+B, Color + B, Power + B, PW +Color+ B, Power + PW +B.

\*Intraoperative includes abdominal, thoracic, and vascular etc.

\*\*Small organ-breast, thyroid, testes, etc.

Note 1: Tissue Harmonic Imaging. The feature does not use contrast agents.

Note 2: Smart3D

Note 3: 4D(Real-time 3D)

Note 4: iScape

Note 5: TDI

Note 6: Contrast Imaging

Note 7: Color M

Note 8: Biopsy Guidance

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation(ODE)

Prescription USE (Per 21 CFR 801.109)

K092691  
 (Division Sign-Off)

Division of Reproductive, Abdominal and  
 Radiological Devices

510(k) Number

*[Signature]*

## Diagnostic Ultrasound Indications for Use Form

System \_\_\_\_\_ Transducer X \_\_\_\_\_  
 Model: 3C5A, C5-2  
 510(k) Number(s) \_\_\_\_\_

Clinical Application	Mode of Operation							
	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Combined (specify)	Other (specify)
Ophthalmic								
Fetal	N	N	N		N	N	N	Note 1, 2, 4,7,8
Abdominal	N	N	N		N	N	N	Note 1, 2, 4,7,8
Intraoperative (specify)*								
Intraoperative (Neuro)								
Laparoscopic								
Pediatric	N	N	N		N	N	N	Note 1, 2, 4,7,8
Small organ(specify)**								
Neonatal Cephalic								
Adult Cephalic								
Trans-rectal								
Trans-vaginal								
Trans-urethral								
Trans-esoph.(non-Card.)								
Musculo-skeletal Conventional	N	N	N		N	N	N	Note 1, 2, 4,7,8
Musculo-skeletal Superficial								
Intravascular								
Cardiac Adult								
Cardiac Pediatric								
Intravascular (Cardiac)								
Trans-esoph.(Cardiac)								
Intra-Cardiac								
Peripheral Vascular	N	N	N		N	N	N	Note 1, 2, 4,7,8
Other (specify)								

N=new indication; P=previously cleared by FDA; E=added under Appendix E

Additional comments: Combined modes: B+M, PW+B, Color + B, Power + B, PW +Color+ B, Power + PW +B.

\*Intraoperative includes abdominal, thoracic, and vascular etc.

\*\*Small organ-breast, thyroid, testes, etc.

Note 1: Tissue Harmonic Imaging. The feature does not use contrast agents.

Note 2: Smart3D

Note 3: 4D(Real-time 3D)

Note 4: iScape

Note 5: TDI

Note 6: Contrast Imaging

Note 7: Color M

Note 8: Biopsy Guidance

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation(ODE)

Prescription USE (Per 21 CFR 801.109)

K092691  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal and  
 Radiological Devices  
 510(k) Number for K092691

## Diagnostic Ultrasound Indications for Use Form

System \_\_\_\_\_ Transducer X  
 Model: V10-4, V10-4B  
 510(k) Number(s) \_\_\_\_\_

Clinical Application	Mode of Operation							
	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Combined (specify)	Other (specify)
Ophthalmic								
Fetal	N	N	N		N	N	N	Note 1, 2, 4, 7, 8
Abdominal								
Intraoperative (specify)*								
Intraoperative (Neuro)								
Laparoscopic								
Pediatric								
Small organ(specify)**								
Neonatal Cephalic								
Adult Cephalic								
Trans-rectal	N	N	N		N	N	N	Note 1, 2, 4, 7, 8
Trans-vaginal	N	N	N		N	N	N	Note 1, 2, 4, 7, 8
Trans-urethral								
Trans-esoph.(non-Card.)								
Musculo-skeletal Conventional								
Musculo-skeletal Superficial								
Intravascular								
Cardiac Adult								
Cardiac Pediatric								
Intravascular (Cardiac)								
Trans-esoph.(Cardiac)								
Intra-Cardiac								
Peripheral Vascular								
Other (specify)***								

N=new indication; P=previously cleared by FDA; E=added under Appendix E

Additional comments: Combined modes: B+M, PW+B, Color + B, Power + B, PW +Color+ B, Power + PW +B.

\*Intraoperative includes abdominal, thoracic, and vascular etc.

\*\*Small organ-breast, thyroid, testes, etc.

\*\*Small organ-breast, thyroid, testes, etc.

Note 1: Tissue Harmonic Imaging. The feature does not use contrast agents.

Note 2: Smart3D

Note 3: 4D(Real-time 3D)

Note 4: iScape

Note 5: TDI

Note 6: Contrast Imaging

Note 7: Color M

Note 8: Biopsy Guidance

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRII, Office of Device Evaluation(ODE)

Prescription USE (Per 21 CFR 801.109)

1092691  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal and  
 Radiological Devices  
 510(k) Number 1092691

## Diagnostic Ultrasound Indications for Use Form

System \_\_\_\_\_ Transducer X  
 Model: 6C2  
 510(k) Number(s) \_\_\_\_\_

Clinical Application	Mode of Operation							
	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Combined (specify)	Other (specify)
Ophthalmic								
Fetal								
Abdominal	N	N	N		N	N	N	Note 1, 2, 4,7,8
Intraoperative (specify)*								
Intraoperative (Neuro)								
Laparoscopic								
Pediatric	N	N	N		N	N	N	Note 1, 2, 4,7,8
Small organ(specify)**								
Neonatal Cephalic	N	N	N		N	N	N	Note 1, 2, 4,7,8
Adult Cephalic	N	N	N		N	N	N	Note 1, 2, 4,7,8
Trans-rectal								
Trans-vaginal								
Trans-urethral								
Trans-esoph.(non-Card.)								
Musculo-skeletal Conventional	N	N	N		N	N	N	Note 1, 2, 4,7,8
Musculo-skeletal Superficial	N	N	N		N	N	N	Note 1, 2, 4,7,8
Intravascular								
Cardiac Adult								
Cardiac Pediatric								
Intravascular (Cardiac)								
Trans-esoph.(Cardiac)								
Intra-Cardiac								
Peripheral Vascular	N	N	N		N	N	N	Note 1, 2, 4,7,8
Other (specify)								

N=new indication; P=previously cleared by FDA; E=added under Appendix E

Additional comments: Combined modes: B+M, PW+B, Color + B, Power + B, PW + Color+ B, Power + PW + B.

\*Intraoperative includes abdominal, thoracic, and vascular etc.

\*\*Small organ-breast, thyroid, testes, etc.

Note 1: Tissue Harmonic Imaging. The feature does not use contrast agents.

Note 2: Smart3D

Note 3: 4D(Real-time 3D)

Note 4: iScape

Note5: TDI

Note6: Contrast Imaging

Note7: Color M

Note8: Biopsy Guidance

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation(ODE)

Prescription USE (Per 21 CFR 801.109)

1092691  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal and  
 Radiological Devices  
 510(k) Number \_\_\_\_\_

## Diagnostic Ultrasound Indications for Use Form

System \_\_\_\_\_ Transducer X  
 Model: 7L4A, 7L5, L12-4, L7-3, L11-4  
 510(k) Number(s) \_\_\_\_\_

Clinical Application	Mode of Operation							
	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Combined (specify)	Other (specify)
Ophthalmic								
Fetal								
Abdominal	N	N	N		N	N	N	Note 1,2, 4,7,8
Intraoperative (specify)*								
Intraoperative (Neuro)								
Laparoscopic								
Pediatric	N	N	N		N	N	N	Note 1,2, 4,7,8
Small organ(specify)**	N	N	N		N	N	N	Note 1,2, 4,7,8
Neonatal Cephalic	N	N	N		N	N	N	Note 1,2, 4,7,8
Adult Cephalic								
Trans-rectal								
Trans-vaginal								
Trans-urethral								
Trans-esoph.(non-Card.)								
Musculo-skeletal Conventional	N	N	N		N	N	N	Note 1,2, 4,7,8
Musculo-skeletal Superficial	N	N	N		N	N	N	Note 1,2, 4,7,8
Intravascular								
Cardiac Adult								
Cardiac Pediatric								
Intravascular (Cardiac)								
Trans-esoph.(Cardiac)								
Intra-Cardiac								
Peripheral Vascular	N	N	N		N	N	N	Note 1,2, 4,7,8
Other (specify)***								

N=new indication; P=previously cleared by FDA; E=added under Appendix E

Additional comments: Combined modes: B+M, PW+B, Color + B, Power + B, PW +Color+ B, Power + PW +B.

\*Intraoperative includes abdominal, thoracic, and vascular etc.

\*\*Small organ-breast, thyroid, testes, etc.

Note 1: Tissue Harmonic Imaging. The feature does not use contrast agents.

Note 2: Smart3D

Note 3:4D(Real-time 3D)

Note 4: iScape

Note5: TDI

Note6: Contrast Imaging

Note7: Color M

Note8: Biopsy Guidance

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation(ODE)

Prescription USE (Per 21 CFR 801.109)

KC92691  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal and  
 Radiological Devices  
 510(k) Number Logan W. W. W.

## Diagnostic Ultrasound Indications for Use Form

System \_\_\_\_\_ Transducer X  
 Model: L14-6  
 510(k) Number(s) \_\_\_\_\_

Clinical Application	Mode of Operation							
	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Combined (specify)	Other (specify)
Ophthalmic								
Fetal								
Abdominal	N	N	N		N	N	N	Note 1,2, 4,7
Intraoperative (specify)*								
Intraoperative (Neuro)								
Laparoscopic								
Pediatric	N	N	N		N	N	N	Note 1,2, 4,7
Small organ(specify)**	N	N	N		N	N	N	Note 1,2, 4,7
Neonatal Cephalic	N	N	N		N	N	N	Note 1,2, 4,7
Adult Cephalic								
Trans-rectal								
Trans-vaginal								
Trans-urethral								
Trans-esoph.(non-Card.)								
Musculo-skeletal Conventional	N	N	N		N	N	N	Note 1,2, 4,7
Musculo-skeletal Superficial	N	N	N		N	N	N	Note 1,2, 4,7
Intravascular								
Cardiac Adult								
Cardiac Pediatric								
Intravascular (Cardiac)								
Trans-esoph.(Cardiac)								
Intra-Cardiac								
Peripheral Vascular	N	N	N		N	N	N	Note 1,2, 4,7
Other (specify)***								

N=new indication; P=previously cleared by FDA; E=added under Appendix E

Additional comments: Combined modes: B+M, PW+B, Color + B, Power + B, PW +Color+ B, Power + PW +B.

\*Intraoperative includes abdominal, thoracic, and vascular etc.

\*\*Small organ-breast, thyroid, testes, etc.

Note 1: Tissue Harmonic Imaging. The feature does not use contrast agents.

Note 2: Smart3D

Note 3:4D(Real-time 3D)

Note 4: iScape

Note5: TDI

Note6: Contrast Imaging

Note7: Color M

Note8: Biopsy Guidance

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation(ODE)

Prescription USE (Per 21 CFR 801.109)

K092691  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal and  
 Radiological Devices  
 510(k) Number Logan M. Whyte

## Diagnostic Ultrasound Indications for Use Form

System \_\_\_\_\_ Transducer X  
 Model: 2P2  
 510(k) Number(s) \_\_\_\_\_

Clinical Application	Mode of Operation							
	B	M	PW D	CWD	Color Doppler	Amplitude Doppler	Combined (specify)	Other (specify)
Ophthalmic								
Fetal								
Abdominal	N	N	N	N	N	N	N	Note 1, 2,5,7,8
Intraoperative (specify)*								
Intraoperative (Neuro)								
Laparoscopic								
Pediatric	N	N	N	N	N	N	N	Note 1, 2,5,7,8
Small organ(specify)**								
Neonatal Cephalic	N	N	N	N	N	N	N	Note 1, 2,5,7,8
Adult Cephalic	N	N	N	N	N	N	N	Note 1, 2,5,7,8
Trans-rectal								
Trans-vaginal								
Trans-urethral								
Trans-esoph.(non-Card.)								
Musculo-skeletal Conventional								
Musculo-skeletal Superficial								
Intravascular								
Cardiac Adult	N	N	N	N	N	N	N	Note 1, 2,5,7,8
Cardiac Pediatric	N	N	N	N	N	N	N	Note 1, 2,5,7,8
Intravascular (Cardiac)								
Trans-esoph.(Cardiac)								
Intra-Cardiac								
Peripheral Vascular								
Other (specify)***								

N=new indication; P=previously cleared by FDA; E=added under Appendix E

Additional comments: Combined modes: B+M, PW+B, Color + B, Power + B, PW +Color+ B, Power + PW +B.

\*Intraoperative includes abdominal, thoracic, and vascular etc.

\*\*Small organ-breast, thyroid, testes, etc.

Note 1: Tissue Harmonic Imaging. The feature does not use contrast agents.

Note 2: Smart3D

Note 3:4D(Real-time 3D)

Note 4: iScape

Note5: TDI

Note6: Contrast Imaging

Note7: Color M

Note8: Biopsy Guidance

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation(ODE)

Prescription USE (Per 21 CFR 801.109)

K092691  
 (Division Sign-Off)

Division of Reproductive, Abdominal and  
 Radiological Devices

510(k) Number Joan M. W.

## Diagnostic Ultrasound Indications for Use Form

System \_\_\_\_\_ Transducer X  
 Model: \_\_\_\_\_ 4CD4  
 510(k) Number(s) \_\_\_\_\_

Clinical Application	Mode of Operation							
	B	M	PW D	CWD	Color Doppler	Amplitude Doppler	Combined (specify)	Other (specify)
Ophthalmic								
Fetal	N	N	N		N	N	N	Note 1, 2, 3, 4, 7
Abdominal	N	N	N		N	N	N	Note 1, 2, 3, 4, 7
Intraoperative (specify)*								
Intraoperative (Neuro)								
Laparoscopic								
Pediatric	N	N	N		N	N	N	Note 1, 2, 3, 4, 7
Small organ(specify)**								
Neonatal Cephalic								
Adult Cephalic								
Trans-rectal								
Trans-vaginal								
Trans-urethral								
Trans-esoph.(non-Card.)								
Musculo-skeletal Conventional								
Musculo-skeletal Superficial								
Intravascular								
Cardiac Adult								
Cardiac Pediatric								
Intravascular (Cardiac)								
Trans-esoph.(Cardiac)								
Intra-Cardiac								
Peripheral Vascular								
Other (specify)***								

N=new indication; P=previously cleared by FDA; E=added under Appendix E

Additional comments: Combined modes: B+M, PW+B, Color + B, Power + B, PW + Color+ B, Power + PW + B.

\*Intraoperative includes abdominal, thoracic, and vascular etc.

\*\*Small organ-breast, thyroid, testes, etc.

Note 1: Tissue Harmonic Imaging. The feature does not use contrast agents.

Note 2: Smart3D

Note 3: 4D(Real-time 3D)

Note 4: iScape

Note 5: TDI

Note 6: Contrast Imaging

Note 7: Color M

Note 8: Biopsy Guidance

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation(ODE)

Prescription USE (Per 21 CFR 801.109)

K092691  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal and  
 Radiological Devices  
 510(k) Number \_\_\_\_\_